Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 4
1999 4
2000 1
2001 3
2002 6
2003 8
2004 5
2005 5
2006 1
2007 3
2008 4
2009 6
2010 4
2011 5
2012 4
2013 4
2014 4
2015 1
2016 1
2018 2
2019 1
2020 1
2021 1
2022 1
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

81 results
Results by year
Filters applied: . Clear all
Page 1
Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP.
Mester A, Lucaciu O, Ciobanu L, Apostu D, Ilea A, Campian RS. Mester A, et al. Bosn J Basic Med Sci. 2018 Aug 1;18(3):217-223. doi: 10.17305/bjbms.2018.3133. Bosn J Basic Med Sci. 2018. PMID: 29984679 Free PMC article. Review.
Oral lichen planus (OLP) is a chronic inflammatory disease characterized by the occurrence of multiple, symmetrical lesions in the oral cavity. ...Surgical intervention is recommended for isolated lesions. In patients with HCV, monotherapy with interferon (IF
Oral lichen planus (OLP) is a chronic inflammatory disease characterized by the occurrence of multiple, symmetrical lesions in the
Telaprevir: an oral protease inhibitor for hepatitis C virus infection.
Kim JJ, Culley CM, Mohammad RA. Kim JJ, et al. Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33. doi: 10.2146/ajhp110123. Am J Health Syst Pharm. 2012. PMID: 22180548 Review.
In Phase II clinical trials, triple therapy (telaprevir with peginterferon alfa and ribavirin) demonstrated 20-39% higher rates of sustained virological response (SVR) versus standard therapy (peginterferon alfa and ribavirin) in patients with chronic HCV genotype 1 …
In Phase II clinical trials, triple therapy (telaprevir with peginterferon alfa and ribavirin) demonstrated 20-39% higher rates of su …
A prospective and randomized study using ribavirin as monotherapy for the treatment of naïve patients with chronic hepatitis C.
Felipe M, Silva AE, Lopes EP, Figueiredo VM, Cruz CN, Oliveira PM, Granero L, Lanzoni V, Ferraz LG. Felipe M, et al. Braz J Infect Dis. 2000 Aug;4(4):183-91. Braz J Infect Dis. 2000. PMID: 11008222 Clinical Trial.
In order to evaluate the response to ribavirin in previously untreated patients with chronic hepatitic C, 39 patients were selected for a double-blind prospective and randomized trial, and divided into two groups: ribavirin-group (19 patients) and placebo-group (20 …
In order to evaluate the response to ribavirin in previously untreated patients with chronic hepatitic C, 39 patients were selected f …
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
August-Jörg BS, Borovicka J, Dufour JF, Gonvers JJ, Henz S, Hermann R, Meyenberger C, Weitz M, Renner EL; Swiss Association for the Study of the Liver. August-Jörg BS, et al. Swiss Med Wkly. 2003 Aug 23;133(33-34):455-60. doi: 10.4414/smw.2003.10300. Swiss Med Wkly. 2003. PMID: 14625812 Free article. Clinical Trial.
BACKGROUND/AIM: Roughly 50% of patients with chronic hepatitis C, who relapsed after a previous monotherapy with interferon alpha, will respond in a sustained fashion to 24 weeks of re-therapy with the combination of interferon alpha plus ribavirin. ...METHODS: Inte …
BACKGROUND/AIM: Roughly 50% of patients with chronic hepatitis C, who relapsed after a previous monotherapy with interferon alpha, wi …
Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.
Rose L, Bias TE, Mathias CB, Trooskin SB, Fong JJ. Rose L, et al. Ann Pharmacother. 2014 Aug;48(8):1019-1029. doi: 10.1177/1060028014534194. Epub 2014 May 8. Ann Pharmacother. 2014. PMID: 24811396 Review.
DATA SYNTHESIS: Sofosbuvir is an NS5B polymerase inhibitor that was approved for use by the Food and Drug Administration in December 2013 for the treatment of chronic HCV in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) for genotype 1. Additionally, i …
DATA SYNTHESIS: Sofosbuvir is an NS5B polymerase inhibitor that was approved for use by the Food and Drug Administration in December 2013 fo …
Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, Changchien CS. Hung CH, et al. J Gastroenterol Hepatol. 2005 May;20(5):727-32. doi: 10.1111/j.1440-1746.2005.03791.x. J Gastroenterol Hepatol. 2005. PMID: 15853986 Clinical Trial.
BACKGROUND: Patients with dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infection have responded poorly to interferon (IFN) monotherapy. The purpose of the present paper was to assess the effect of combined IFN-alpha and ribavirin therapy in patients infe …
BACKGROUND: Patients with dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infection have responded poorly to interferon (IFN) mo
Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P. Donato MF, et al. Int J Artif Organs. 2013 Jan;36(1):63-8. doi: 10.5301/ijao.5000166. Int J Artif Organs. 2013. PMID: 23280083 Review.
After 11 months, IFN-therapy was interrupted and the patient continued low-dose ribavirin monotherapy (200 mg once per day) for one additional year- remission of proteinuria (<0.3 g/24 h) and hematuria persisted with intact kidney function. ...Further evidence is …
After 11 months, IFN-therapy was interrupted and the patient continued low-dose ribavirin monotherapy (200 mg once per day) fo …
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.
Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Preston SL, et al. Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6. doi: 10.1128/AAC.43.10.2451. Antimicrob Agents Chemother. 1999. PMID: 10508023 Free PMC article. Clinical Trial.
The objective of this study was to determine the absolute bioavailability of ribavirin with an intravenous formulation containing ribavirin labeled with the stable isotope (13)C(3) ((13)C(3)-ribavirin) and unlabeled oral ribavirin. Six healthy v …
The objective of this study was to determine the absolute bioavailability of ribavirin with an intravenous formulation containing …
Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Smee DF, et al. Antimicrob Agents Chemother. 2009 May;53(5):2120-8. doi: 10.1128/AAC.01012-08. Epub 2009 Mar 9. Antimicrob Agents Chemother. 2009. PMID: 19273672 Free PMC article.
Double combinations of amantadine, oseltamivir (or the cell culture-active form, oseltamivir carboxylate), and ribavirin were used. Amantadine-oseltamivir carboxylate and amantadine-ribavirin combinations showed synergistic interactions over a range of doses against …
Double combinations of amantadine, oseltamivir (or the cell culture-active form, oseltamivir carboxylate), and ribavirin were used. A …
Efficacy of ribavirin monotherapy following combination therapy with interferon alfa-2b and ribavirin for patients with chronic hepatitis C.
Nagayama R, Tanaka A, Ankoh H, Narita T, Izumi M, Miyake K, Takikawa H. Nagayama R, et al. Hepatol Res. 2005 Jun;32(2):101-6. doi: 10.1016/j.hepres.2005.02.007. Hepatol Res. 2005. PMID: 15876551
We hypothesed that ribavirin monotherapy after 6 months of combination therapy may improve sustained viral and biochemical responses, and conducted a prospective, randomized and controlled study. ...In cases without sustained viral responses, serum ALT levels at bas …
We hypothesed that ribavirin monotherapy after 6 months of combination therapy may improve sustained viral and biochemical res …
81 results